Matthew O'COnnor

Matthew O'COnnor

Auto-generated profile, based on publicly available information

Matthew O'COnnor

Department of Electrophysiology, Auckland City Hospital, Auckland, New Zealand

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
JMJeremy P. Moore
Jeremy P. Moore
Natasja M.S. de GrootNatasja M.S. de Groot
Natasja M.S. de Groot
MOMatthew O’cOnnor
Matthew O’cOnnor
DCDaniel Cortez
Daniel Cortez
JSJonathan Su
Jonathan Su
ÓCÓscar Cano
Óscar Cano

11 November 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
MOMatthew O’cOnnor
Matthew O’cOnnor
OROmar Riad
Omar Riad
RSRui Shi
Rui Shi
DHDan Hunnybun
Dan Hunnybun
WLWei Li
Wei Li
TWTom Wong
Tom Wong
Left bundle branch area pacing (LBBAP) has been shown to be effective and safe. Limited data are available on LBBAP in the congenital heart disease (CHD) population. This study aims to describe the feasibility and safety of LBBAP in CHD patients compared with non-CHD patients. This is a single-centre, non-randomized observational study recruiting consecutive patients with bradycardia indication. Demographic data, ECGs, imaging, and procedural data including lead parameters were recorded. A total of 39 patients were included: CHD group (n = 13) and non-CHD group (n = 26). Congenital heart disease patients were younger (55 ± 14.5 years vs. 73.2 ± 13.1, P < 0.001). Acute success was achieved in all CHD patients and 96% (25/26) of non-CHD patients. No complications were encountered in either group. The procedural time for CHD patients was comparable (96.4 ± 54 vs. 82.1 ± 37.9 min, P = 0.356). Sheath reshaping was required in 7 of 13 CHD patients but only in 1 of 26 non-CHD patients, reflecting the complex and distorted anatomy of the patients in this group. Lead parameters were similar in both groups; R wave (11 ± 7 mV vs. 11.5 ± 7.5, P = 0.881) and pacing threshold (0.6 ± 0.3 V vs. 0.7 ± 0.3, P = 0.392). Baseline QRS duration was longer in the CHD group (150 ± 28.2 vs. 118.6 ± 26.6 ms, P = 0.002). Despite a numerically greater reduction in QRS and a similar left ventricular activation time (65.9 ± 6.2 vs. 67 ± 16.8 ms, P = 0.840), the QRS remained longer in the CHD group (135.5 ± 22.4 vs. 106.9 ± 24.7 ms, P = 0.005). Left bundle branch area pacing is feasible and safe in CHD patients as compared to that in non-CHD patients. Procedural and fluoroscopy times did not differ between both groups. Lead parameters were satisfactory and stable over a short-term follow-up.

31 July 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
MOMatthew O’cOnnor
Matthew O’cOnnor
UBUmberto Barbero
Umberto Barbero
DKDaniel B Kramer
Daniel B Kramer
ALAngela Lee
Angela Lee
AHAlina Hua
Alina Hua
TWTom Wong
Tom Wong
Leadless pacemakers (LPs) may mitigate the risk of lead failure and pocket infection related to conventional transvenous pacemakers. Atrial LPs are currently being investigated. However, the optimal and safest implant site is not known. We aimed to evaluate the right atrial (RA) anatomy and the adjacent structures using complementary analytic models [gross anatomy, cardiac magnetic resonance imaging (MRI), and computer simulation], to identify the optimal safest location to implant an atrial LP human. Wall thickness and anatomic relationships of the RA were studied in 45 formalin-preserved human hearts. In vivo RA anatomy was assessed in 100 cardiac MRI scans. Finally, 3D collision modelling was undertaken assessing for mechanical device interaction. Three potential locations for an atrial LP were identified; the right atrial appendage (RAA) base, apex, and RA lateral wall. The RAA base had a wall thickness of 2.7 ± 1.6 mm, with a low incidence of collision in virtual implants. The anteromedial recess of the RAA apex had a wall thickness of only 1.3 ± 0.4 mm and minimal interaction in the collision modelling. The RA lateral wall thickness was 2.6 ± 0.9 mm but is in close proximity to the phrenic nerve and sinoatrial artery. Based on anatomical review and 3D modelling, the best compromise for an atrial LP implantation may be the RAA base (low incidence of collision, relatively thick myocardial tissue, and without proximity to relevant epicardial structures); the anteromedial recess of the RAA apex and lateral wall are alternate sites. The mid-RAA, RA/superior vena cava junction, and septum appear to be sub-optimal fixation locations. Attitudinal view of the right atrium demonstrating the three proposed optimal locations for the implantation of an atrial leadless pacemaker; (1) anteromedial RAA apex, (2) base of the RAA, (3) right atrial lateral wall. AM, anteromedial (aspect of the RAA); CS, coronary sinus; CT, crista terminalis; EV, eustachian valve; IVC, inferior vena cava; PL, posterolateral (aspect of the RAA); RAA, right atrial appendage; RCA, right coronary artery; RVOT, right ventricular outflow tract; SB, septal bundle; SC, supraventricular crest; SVC, superior vena cava; TV, tricuspid valve.

14 April 2018 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
MOMatthew O'COnnor
Matthew O'COnnor
DHDarren Hooks
Darren Hooks
MWMatthew Webber
Matthew Webber
BSBijia Shi
Bijia Shi
SMStephanie Morrison
Stephanie Morrison
PLPeter Larsen
Peter Larsen

17 April 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
CLCarsten Lennerz
Carsten Lennerz
CSClaudia Schaarschmidt
Claudia Schaarschmidt
PBPatrick Blažek
Patrick Blažek
KKKatharina Knoll
Katharina Knoll
MKMarc Kottmaier
Marc Kottmaier
MOMatthew O'COnnor
Matthew O'COnnor
Aims: Battery electric vehicle (BEV) sales and use are rapidly expanding. Battery electric vehicles, along with their charging stations, are a potential source of electromagnetic interference (EMI) for patients with cardiac implantable electronic devices (CIEDs). The new ‘high-power’ charging stations have the potential to create strong electromagnetic fields and induce EMI in CIEDs, and their safety has not been evaluated. Methods and results: A total of 130 CIED patients performed 561 charges of four BEVs and a test vehicle (350 kW charge capacity) using high-power charging stations under continuous 6-lead electrocardiogram monitoring. The charging cable was placed directly over the CIED, and devices were programmed to maximize the chance of EMI detection. Cardiac implantable electronic devices were re-interrogated after patients charged all BEVs and the test vehicle for evidence of EMI. There were no incidences of EMI, specifically no over-sensing, pacing inhibition, inappropriate tachycardia detection, mode switching, or spontaneous reprogramming. The risk of EMI on a patient-based analysis is 0/130 [95% confidence interval (CI) 0%–2%], and the risk of EMI on a charge-based analysis is 0/561 (95% CI 0%–0.6%). The effective magnetic field along the charging cable was 38.65 µT and at the charging station was 77.9 µT. Conclusions: The use of electric cars with high-power chargers by patients with cardiac devices appears to be safe with no evidence of clinically relevant EMI. Reasonable caution, by minimizing the time spent in close proximity with the charging cables, is still advised as the occurrence of very rare events cannot be excluded from our results.

21 September 2022 in JACC: Case Reports
Verified
Journal Article
Open access
NBNeil Bodagh
Neil Bodagh
KMKatarzyna Małaczyńska-Rajpold
Katarzyna Małaczyńska-Rajpold
WEWilliam Eysenck
William Eysenck
MOMatthew O’cOnnor
Matthew O’cOnnor
TWTom Wong
Tom Wong
We present the case of an 81-year-old woman with a background of situs inversus with dextrocardia who was successfully treated for tachycardia-bradycardia syndrome with left bundle area pacing. This report describes how this approach can circumvent the limitations of other pacing approaches to optimize patient outcomes. (Level of Difficulty: Intermediate.)